Earnings ·
Tvardi Therapeutics reported second quarter 2026 financial results and business updates
TVRDTvardi Therapeutics, Inc.
Tvardi Therapeutics reported second quarter 2026 financial results and business updates. The company announced topline healthy volunteer data for its next-generation STAT3 inhibitor TTI-109, confirming improved tolerability and target engagement, and selected ulcerative colitis as the initial indication. R&D expenses decreased to $4.0 million from $5.8 million in the prior year period, while G&A expenses fell to $2.6 million from $3.1 million. The company reported a net loss of $6.5 million compared to a net income of $4.2 million previously, primarily due to the absence of a non-cash gain on convertible notes. Cash and short-term investments stood at $15.8 million as of June 30, 2026, sufficient through Q3 2027. Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for inflammatory and proliferative diseases.